

## Bora Pharmaceuticals Reports Consolidated Revenue of NT\$2.02 Billion in April

### 保瑞公告 4 月自結合併營收新台幣 20 億 2 仟萬元

Taipei, Taiwan, May 9, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for April 2025 reached NT\$2.02 billion, an increase of 22.8% compared to same period last year. During the month, **CDMO business** continues to perform while **pharma sales business** (formerly “Commercial”) rebounded strongly against the softness in the previous quarter driven by market share gain across generics led by DLS and specialties led by VIGAFYDE.

台北，台灣，2025 年 5 月 9 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 4 月自結合併營收為新台幣 20 億 2 仟萬元，較去年同期增長 22.8%；CDMO 表現維持高檔，而全球銷售業務主要受惠 DLS 為首的學名藥與 VIGAFYDE 為首的特殊專科用藥市佔率擴張，營收較前一季大幅反彈。

Following portfolio optimization in Q1, we have greater confidence in our current product mix. Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). VIGAFYDE’s sequentially growth also contributed to a stronger product mix. This recovery underscores our agility and the resilience of dual-engine strategy. We remain firmly focused on improving gross margin and free cash flow quality. As the ahead-of-schedule phase-out of non-strategic products in the previous quarter, we enter Q2 with a clear runway to focus on reallocating resources toward higher-value and specialty offerings. This positions us well to accelerate the transformation of our businesses.

在第一季較目標提早完成產品組合優化後，我們對現有產品組合的競爭力更具信心。DLS 雖然於前一季個季度受市場需求影響銷售較淡，然競爭者第二季初出現供應鏈問題，保瑞隨即補足缺口，成功搶下市佔，此應變能力正是雙引擎策略所體現的營運韌性與供應鏈效率；加上 KCL、Diltiazem 及 VIGAFYDE 等新產品穩定貢獻，銷售動能已於 4 月顯著回升。保瑞將持續專注於毛利率提升與現金流品質，將資源投注至高價值與特殊專科品項，推進集團穩健成長。

#### Recent Investor Conference

Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company’s Q1’25 financial and business results and outlook.

English Online Earnings Presentation Link: <https://www.zucast.com/event/54SiM5il/subscribe/create>

The 2025 Annual General Shareholders’ Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.

Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.

## 年度營運報告及法說會資訊

- 保瑞將在台灣時間 5 月 15 日上午 7:00 點自辦英文線上業績發表會，以及於 5 月 16 日下午 2:00 受邀參加台新證券假君悅酒店舉辦之業績發表會，向投資人說明公司 2025 年第一季財務與業務報告及 2025 年展望。
- 保瑞將於 6 月 4 日至 5 日於紐約參加 Jefferies Global Healthcare Conference，您希望與管理層面對面會議請聯繫您的 Jefferies 業務。
- 英文線上業績發表會連結：<http://www.zucast.com/webcast/54SiM5il>

### About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracorpcdmo.com>

### 關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracorpcdmo.com>

### Investor/Media enquiries

Nadiya Chen, Investor Relations

+886 2 790-1555 Ext. 9108

Email: [Nadiya.Chen@bora-corp.com](mailto:Nadiya.Chen@bora-corp.com)

### 新聞聯繫人：

投資人關係 陳荻雅

電話：(02) 2790-1555 #9108

Email: [Nadiya.Chen@bora-corp.com](mailto:Nadiya.Chen@bora-corp.com)